As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

Qure’s AMT-130 faces FDA efficacy doubts after 12-month data. QURE's upside now hinges on political pressure. Read here for ...

This transition is explored in “Embodied Artificial Intelligence in Healthcare: A Systematic Review of Robotic Perception, ...

A 5-day amoxicillin challenge was feasible for evaluating delayed penicillin allergy, with more than 80% of participants ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical ...

Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...

Socioemotional skills programs are widely used to promote economic empowerment, yet their returns may vary by skill-type and ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

“Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 ...

Earnings call Profound Medical reported Q4 2025 revenue of CAD 6 million, up 43% year-over-year, with gross margin at 67% and a net loss of CAD 8.2 million. Management anticipates continued high ...

A key advantage of using RWD in a natural history study is gaining diverse and representative data. RWD covers broad patient ...